Merck & Co Inc

NYSE: MRK
$128.80
-$0.42 (-0.3%)
Closing price May 1, 2024
Merck & Co Inc is a global healthcare leader known for its innovative pharmaceuticals and animal health products. With a rich history dating back to 1891, Merck has made significant strides in oncology, immunology, neuroscience, and more, offering well-known brands like Keytruda and Januvia. Its pharmaceutical segment focuses on human health, while the Animal Health division provides veterinary pharmaceuticals and services. Merck collaborates with industry giants like AstraZeneca and Bayer, emphasizing its commitment to advancing healthcare across both human and animal sectors.
Monday’s top analyst upgrades and downgrades included Apple, Coca-Cola, CommScope, Coupa Software, GoPro, HubSpot, Merck, NetApp, Pfizer, Shopify, Spirit Airlines and Warner Music.
Tuesday’s top analyst upgrades and downgrades included Bloomin' Brands, Boston Beer, Bumble, Goldman Sachs, Juniper Networks, Merck, Moderna, Petco Health, Southern Company, Spirit Airlines and...
Merck, Stryker and these other companies are expected to lift the dividends they pay to shareholders, and their stocks are rated Buy across Wall Street, making them excellent total return candidates.
Monday’s top analyst upgrades and downgrades included Affirm, BlackRock, Deere, Dick's Sporting Goods, Dollar Tree, Intercontinental Exchange, Mastercard, Merck, Nordstrom, Petrobras and Pure...
McCormick, Merck and these other top companies are expected to lift the dividends they pay to shareholders, and their stocks are rated Buy across Wall Street, making them excellent total return...
Merck, Nike and these other top companies are expected to lift the dividends they pay to shareholders, and their stocks are rated Buy across Wall Street, making them excellent total return candidates.
Monday afternoon's analyst upgrades and downgrades included Bristol-Myers Squibb, Intel, Merck, Newell Brands, Snap, Spotify Technology and Tilray.
In this massively overbought market, health care stocks could benefit from a shift toward more defensive sectors. These five offer strong balance sheets, attractive dividend yields and improved cost...
While the quantitative easing soon will begin to dwindle, it is highly unlikely the Federal Reserve actually will raise interest rates until 2023, so buying blue-chip stocks with solid total return...
The trading action late last week hints that a long-overdue market correction may be coming, so now may be the right time to take some profits and move to calmer waters. These five conservative...
Tuesday’s top analyst upgrades and downgrades included Amgen, Cirrus Logic, Hain Celestial, Johnson & Johnson, Lam Research, Merck, Spotify Technology and Vertex Pharmaceuticals.
These four big pharmaceutical stocks are rated Buy by top Wall Street firms and look like very good ideas for investors, especially now that the market is overbought and the slow seasonal market...
Two pharmaceutical companies and a top media firm are on tap to report quarterly results before markets open on Thursday.
24/7 Wall St. looks at some big analyst upgrades and downgrades that we have seen so far on Tuesday, including Domino’s, Eli Lilly, Harley-Davidson, McDonald’s and Merck.
Among the stocks in Warren Buffett's Berkshire Hathaway portfolio are eight components of the Dow 30, and only three of those are in the green for the year to date.